We demonstrate the impact of taking a platform approach to synthetic biology R&D. We focus on three commercial programs currently underway to produce aromatic molecules in yeast. In each program, Ginkgo is de-risking a partner’s R&D and commercial objectives by applying scale and utilizing iterative learnings from previous programs.
The first program highlights significant progress toward producing a target molecule in yeast for the first time publicly reported. Through iterative rounds of enzyme discovery and optimization, this program yielded a chassis strain with high flux through coumarate, a key bottleneck along the path to the target molecule and variety of other aromatic molecules.
Leveraging this prior work – the “coumarate chassis strain” – a second program for a partner involved in the production of food ingredients had an advanced starting point. Their target is a different set of aromatic molecules produced in yeast downstream of coumarate.
Finally, a third program aims to produce two aromatic molecules, bio-based intermediates for materials, in yeast. This program similarly leverages an advanced starting point – a yeast chassis strain with significant flux through a shared precursor: protocatechuate.